CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

Novo Nordisk 's NVO CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.

CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.

The maker of diabetes and weight-loss drugs Ozempic and Wegovy was in the hot seat Tuesday as Vermont Sen. Bernie Sanders grilled him about high prices in the U.S. that far exceed the cost in

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a congressional committee led by Senator Bernie Sanders: It’s the middlemen.

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss drugs Ozempic and

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.